{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:20:42Z","timestamp":1787721642307,"version":"build-2784847793"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Metabolic bariatric surgery is a highly effective weight-loss intervention. Nevertheless, a non-negligible proportion of patients experience a suboptimal clinical response, which may present as insufficient weight loss or weight regain after an initial loss. In these cases, weight management pharmacotherapy can be considered. We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis. After treatment with incretin receptor agonists, patients who underwent metabolic bariatric surgery, experienced significant weight loss. Meta-analysis showed, at 12 months, a total weight loss of 9.22% with liraglutide and of 9.02% with semaglutide. At 6 months, a mean difference in total weight loss of 4.23% was presented in favor of tirzepatide as compared to semaglutide. No serious adverse events were observed and most reported side effects were non-serious, consisting primarily of mild gastrointestinal symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This data suggests that incretin receptor agonist treatment after metabolic bariatric surgery demonstrated the ability to achieve significant weight loss with a good safety profile, particularly in patients with a suboptimal clinical response, and thus may serve as an alternative rescue therapy to revisional surgery. However, given the substantial heterogeneity across studies, these findings should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022371697<\/jats:ext-link>\n                      , identifier CRD42022371697.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1870008","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:43:57Z","timestamp":1787719437000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery \u2013 a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Mariana","family":"Santos-Pereira","sequence":"first","affiliation":[{"name":"Unit for Multidisciplinary Research in Biomedicine, School of Medicine and Biomedical Sciences,University of Porto","place":["Porto, Portugal"]},{"name":"Laboratory for Integrative and Translocation Research in Population Health (ITR), University of Porto","place":["Porto, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o F.","family":"Frutuoso","sequence":"additional","affiliation":[{"name":"Unit for Multidisciplinary Research in Biomedicine, School of Medicine and Biomedical Sciences,University of Porto","place":["Porto, Portugal"]},{"name":"Laboratory for Integrative and Translocation Research in Population Health (ITR), University of Porto","place":["Porto, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia S.","family":"Pereira","sequence":"additional","affiliation":[{"name":"Unit for Multidisciplinary Research in Biomedicine, School of Medicine and Biomedical Sciences,University of Porto","place":["Porto, Portugal"]},{"name":"Laboratory for Integrative and Translocation Research in Population Health (ITR), University of Porto","place":["Porto, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Unit for Multidisciplinary Research in Biomedicine, School of Medicine and Biomedical Sciences,University of Porto","place":["Porto, Portugal"]},{"name":"Laboratory for Integrative and Translocation Research in Population Health (ITR), University of Porto","place":["Porto, Portugal"]},{"name":"Department of General Surgery, Hospital S\u00e3o Sebasti\u00e3o, Unidade Local de Sa\u00fade de Entre o Douro e Vouga","place":["Santa Maria da Feira, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana P.","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Unit for Multidisciplinary Research in Biomedicine, School of Medicine and Biomedical Sciences,University of Porto","place":["Porto, Portugal"]},{"name":"Laboratory for Integrative and Translocation Research in Population Health (ITR), University of Porto","place":["Porto, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/oby.22045","article-title":"Why is it difficult to lose and maintain large amounts of weight with lifestyle and pharmacologic treatments","volume":"25","author":"Heymsfield","year":"2017","journal-title":"Obesity"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-0499-4","article-title":"Are there really any predictive factors for a successful weight loss after bariatric surgery","volume":"20","author":"Cadena-Obando","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-019-03734-6","article-title":"Weight regain after bariatric surgery\u2014a multicentre study of 9617 patients from Indian Bariatric Surgery Outcome Reporting Group","volume":"29","author":"Baig","year":"2019","journal-title":"Obes Surg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1590\/S0102-67202013000600007","article-title":"Determinants of weight regain after bariatric surgery","volume":"26","author":"Bastos","year":"2013","journal-title":"ABCD Arquivos Brasileiros Cirurgia Digestiva (S\u00e3o Paulo)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-014-1560-z","article-title":"Trends in weight regain following Roux-en-Y gastric bypass (RYGB) bariatric surgery","volume":"25","author":"Cooper","year":"2015","journal-title":"Obes Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-014-1541-2","article-title":"Systematic review of definitions of failure in revisional bariatric surgery","volume":"25","author":"Mann","year":"2015","journal-title":"Obes Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-018-3610-4","article-title":"Lack of standard definitions of primary and secondary (non) responders after primary gastric bypass and gastric sleeve: a systematic review","volume":"29","author":"Bonouvrie","year":"2019","journal-title":"Obes Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11695-023-06913-8","article-title":"IFSO consensus on definitions and clinical practice guidelines for obesity management\u2014an international delphi study","volume":"34","author":"Salminen","year":"2024","journal-title":"Obes Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-023-09801-9","article-title":"Towards precision medicine in bariatric surgery prescription","volume":"24","author":"Pereira","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/por.S471476","article-title":"Therapeutic advances in obesity: how real-world evidence impacts affordability beyond standard of care","volume":"15","author":"Patoulias","year":"2024","journal-title":"Pragmat Obs Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon\u2010like peptide\u20101 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.07.010","article-title":"GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss\u2014chemistry, physiology, and clinical applications","volume":"35","author":"Campbell","year":"2023","journal-title":"Cell Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314631","article-title":"Tirzepatide: a systematic update","volume":"23","author":"Forzano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00423-025-03831-4","article-title":"GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis","volume":"410","author":"Tan","year":"2025","journal-title":"Langenbeck's Arch Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13811","article-title":"Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis","volume":"25","author":"Esparham","year":"2024","journal-title":"Obes Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-024-07127-2","article-title":"Adjuvant glucose-like peptide 1 receptor agonist therapy for suboptimal weight loss after bariatric surgery: a systematic review","volume":"34","author":"Dr\u00e9ant","year":"2024","journal-title":"Obes Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-021-05884-y","article-title":"Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes","volume":"32","author":"Elhag","year":"2022","journal-title":"Obes Surg"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40519-022-01403-9","article-title":"Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery","volume":"27","author":"Muratori","year":"2022","journal-title":"Eating Weight Disorders-Studies Anorexia Bulimia Obes"},{"key":"B24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11695-020-04856-y","article-title":"Reversal of long-term weight regain after Roux-en-Y gastric bypass using liraglutide or surgical revision. A prospective study","volume":"31","author":"Horber","year":"2021","journal-title":"Obes Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-021-05535-2","article-title":"Initial experience with alternate-day liraglutide for weight regain following bariatric surgery","volume":"31","author":"Rubio","year":"2021","journal-title":"Obes Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30157-3","article-title":"Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Miras","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12323","article-title":"Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post\u2010bariatric surgery","volume":"9","author":"Wharton","year":"2019","journal-title":"Clin Obes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-018-3393-7","article-title":"Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery","volume":"28","author":"Rye","year":"2018","journal-title":"Obes Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2016.02.013","article-title":"Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2016","journal-title":"Surg Obes Relat Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-69912013000300005","article-title":"Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery","volume":"40","author":"Pajecki","year":"2013","journal-title":"Rev do Col\u00e9gio Brasileiro Cirurgi\u00f5es"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2024.08.037","article-title":"A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass","volume":"21","author":"Lofton","year":"2025","journal-title":"Surg Obes Relat Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.706","article-title":"Effectiveness and tolerability of liraglutide for the management of weight regain following sleeve gastrectomy","volume":"10","author":"Jamal","year":"2024","journal-title":"Obes Sci Pract"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.2930","article-title":"Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial","volume":"158","author":"Mok","year":"2023","journal-title":"JAMA Surg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00423-023-02805-8","article-title":"The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery","volume":"408","author":"Colbourne","year":"2023","journal-title":"Langenbecks Arch Surg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1183899","article-title":"High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery","volume":"10","author":"Vinciguerra","year":"2023","journal-title":"Front Nutr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13672","article-title":"Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non\u2010surgical and bariatric surgery patients","volume":"21","author":"Suliman","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-022-06211-9","article-title":"The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery\u2014a retrospective analysis","volume":"32","author":"Lautenbach","year":"2022","journal-title":"Obes Surg"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12593","article-title":"Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post\u2010bariatric treatment failure","volume":"13","author":"Lautenbach","year":"2023","journal-title":"Clin Obes"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23922","article-title":"Semaglutide 2.4 mg\/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery","volume":"32","author":"Bonnet","year":"2024","journal-title":"Obesity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100098","article-title":"Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes","volume":"9","author":"Kanai","year":"2024","journal-title":"Obes Pillars"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2025.02.004","article-title":"Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition","volume":"19","author":"Stoll","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1089\/bari.2018.0037","article-title":"Weight loss medications in older adults after bariatric surgery for weight regain or inadequate weight loss: a multicenter study","volume":"13","author":"Stanford","year":"2018","journal-title":"Bariatr Surg Pract Patient Care"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-024-07137-0","article-title":"Semaglutide and tirzepatide for the management of weight recurrence after sleeve gastrectomy: a retrospective cohort study","volume":"34","author":"Jamal","year":"2024","journal-title":"Obes Surg"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/cob.70001","article-title":"Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy","volume":"15","author":"Bahdi","year":"2025","journal-title":"Clin Obes"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-023-06484-8","article-title":"Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study","volume":"33","author":"Jensen","year":"2023","journal-title":"Obes Surg"},{"key":"B46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12902-025-01913-4","article-title":"Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study","volume":"25","author":"Jensen","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23736","article-title":"Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence","volume":"31","author":"Murvelashvili","year":"2022","journal-title":"Obesity"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-024-07181-w","article-title":"Utilization of anti-obesity medications after bariatric surgery: analysis of a large national database","volume":"34","author":"Firkins","year":"2024","journal-title":"Obes Surg"},{"key":"B49","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.soard.2016.10.018","article-title":"The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study","volume":"13","author":"Stanford","year":"2017","journal-title":"Surg Obes Relat Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-007-9536-x","article-title":"Reoperative bariatric surgery","volume":"21","author":"Sarr","year":"2007","journal-title":"Surg Endosc"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2008.11.011","article-title":"Should bariatric revisional surgery be avoided secondary to increased morbidity and mortality","volume":"197","author":"Hallowell","year":"2009","journal-title":"Am J Surg"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e230234","DOI":"10.20945\/2359-4292-2023-0234","article-title":"Use of liraglutide after bariatric surgery: a 36-month follow-up in a real-world setting in Chile","volume":"68","author":"Far\u00edas","year":"2024","journal-title":"Arch Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1381\/0960892054621053","article-title":"Minimal reporting requirements for weight loss: Current methods not ideal","volume":"15","author":"Dixon","year":"2005","journal-title":"Obes Surg"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1870008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:44:03Z","timestamp":1787719443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1870008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":59,"alternative-id":["10.3389\/fendo.2026.1870008"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1870008","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1870008"}}